Data on hyper-activation of GPVI signalling in obese patients: Towards the identification of novel antiplatelet targets in obesity

María N Barrachina; Irene Izquierdo; Lidia Hermida-Nogueira; Aurelio M Sueiro; Esteban Guitián; Felipe F Casanueva; Richard W Farndale; Masaaki Moroi; Stephanie M Jung; María Pardo; Ángel García

doi:10.1016/j.dib.2019.103784

Data on hyper-activation of GPVI signalling in obese patients: Towards the identification of novel antiplatelet targets in obesity

Data Brief. 2019 Feb 28:23:103784. doi: 10.1016/j.dib.2019.103784. eCollection 2019 Apr.

Authors

María N Barrachina^{1

2}, Irene Izquierdo^{1

2}, Lidia Hermida-Nogueira^{1

2}, Aurelio M Sueiro³, Esteban Guitián⁴, Felipe F Casanueva^{2

3}, Richard W Farndale⁵, Masaaki Moroi⁵, Stephanie M Jung⁵, María Pardo^{2

6}, Ángel García^{1

2}

Affiliations

¹ Platelet Proteomics Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade Santiago de Compostela, Spain.
² Instituto de Investigación Sanitaria de Santiago (IDIS), Spain.
³ Grupo de Endocrinología Molecular y Celular, Instituto de Investigación Sanitaria de Santiago (IDIS)/ Servicio de Endocrinología, Xerencia de Xestión Integrada de Santiago (XXS), Spain.
⁴ Mass Spectrometry and Proteomic Unit, Rede de Infraestructuras de Apoio á Investigación e ao Desenvolvemento Tecnolóxico, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
⁵ Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, United Kingdom.
⁶ Grupo Obesidómica - Instituto de Investigación Sanitaria de Santiago (IDIS).

Abstract

This data article is associated with the manuscript "GPVI surface expression and signalling pathway activation are increased in platelets from obese patients: elucidating potential anti-atherothrombotic targets in obesity" [1]. The study refers to a combination of different approaches in order to identify platelet-derived biomarkers in obesity. A total of 34 obese patients and their lean-matched controls were included in the study. We carried out a proteomic and functional (aggregation assays) analysis to find alterations in platelet-derived signalling pathways. After that, biochemical and mechanistic (flow cytometry assays) approaches were done in order to confirm a hyperactivation of the GPVI-related signalling pathway.

Abstract

Grants and funding